Drug details
Ebanga (ansuvimab-zykl for injection, for intravenous use)
type of Monoclonal Antibodies
Ebanga (ansuvimab-zykl) is a Zaire ebolavirus glycoprotein (EBOV GP)-directed human monoclonal antibody indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
This drug may have the following side effects:
- vomiting,
- diarrhea,
- fever,
- low blood pressure (hypotension),
- fast heart rate,
- fast, shallow breathing,
- chills, and
- low blood oxygen